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Abstract 
 
Five disorders currently comprise the ‘Parkinsonian syndromes’, viz. Parkinson’s disease 
(PD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple 
system atrophy (MSA), and corticobasal degeneration (CBD). Differential diagnosis of 
these disorders can be challenging but if ocular signs and symptoms are present they may 
aid clinical diagnosis. Visual problems in the Parkinsonism syndromes may involve 
visual acuity (VA), contrast sensitivity (CS), color vision, pupil reactivity, and eye 
movements; more complex aspects of vision such as reading ability, visuo-spatial 
orientation, the identification and naming of objects, and visual hallucinations. No single 
visual feature can definitively diagnose a specific Parkinsonism syndrome. Nevertheless, 
the presence of visual hallucinations and color vision problems may be more 
characteristic of DLB and PD than CBD or PSP and vertical supranuclear gaze palsy may 
be a significant feature of PSP. In addition, variation in saccadic eye movement (SEM) 
problems may help to distinguish PD and CBD from PSP. A multidisciplinary approach 
is often necessary to manage the visual problems of patients with a Parkinsonism 
syndrome. 
 
Key words: Parkinsonian syndrome; Visual problems; Diagnosis; Saccadic eye 
movements (SEM); Visual hallucinations; Patient management 
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List of abbreviations 
 
AD  Alzheimer’s disease 
AON  Abnormal optokinetic nystagmus 
CBD  Corticobasal degeneration 
CS  Contrast sensitivity 
DLB  Dementia with Lewy bodies 
EEG  Electroencephalogram 
ERG  Electroretinogram 
EOG  Electrooculography 
ERP  Event-related potential 
FSW  Focal slow waves 
GCI  Glial cytoplasmic inclusion 
GFS  Global field synchronization 
REM  Rapid eye movement sleep disorder 
LB  Lewy body 
MAP  Microtubule-associated protein 
MSA  Multiple system atrophy 
NFT  Neurofibrillary tangle 
PD  Parkinsons’s disease 
PERG  Pattern electroretinogram 
PHF  Paired helical filament 
PSP  Progressive supranuclear palsy 
rCBF  Regional cerebral blood flow 
QOL  Quality of life 
SEM  Saccadic eye movements 
SPM  Smooth pursuit movements 
SN  Substantia nigra  
VA  Visual acuity 
VEP  Visual evoked potential 
VOR  Vestibulo-ocular reflex 
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 VSP  Vertical supranuclear gaze palsy 
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1. Introduction 
 
There are five disorders currently included within the ‘Parkinsonism syndromes’, viz., 
Parkinson’s disease (PD),1 dementia with Lewy bodies (DLB),2 progressive supranuclear 
palsy (PSP),3 multiple system atrophy (MSA),4 and corticobasal degeneration (CBD).5 
Patients with a Parkinsonism syndrome exhibit a variety of motor and, non-motor 
symptoms, the latter including loss of motivation, decreased activity, poverty of behavior, 
depression, sleep problems, cognitive impairment, dementia, and autonomic, 
gastrointestinal, and sensory dysfunction.1,6 Sensory dysfunction can affect several 
modalities including visual, auditory and olfactory problems7 and ‘restless legs’ 
syndrome.8 
 
Although criteria have been developed for differential diagnosis within the Parkinsonism 
syndromes,9 identification of individual disorders can be challenging.7 Nevertheless, a 
variety of visual problems may be present including defects in eye movement, pupillary 
function, and in more complex visual tasks involving the ability to judge distance or the 
shape of an object. If visual problems are present, they may provide useful additional 
features to aid clinical diagnosis. In addition, management of the complex variety of 
visual problems will be necessary to maximize the vision of individual patients and 
improve their quality of life (QOL). Hence, this review describes: (1) the clinical and 
pathological features of each syndrome, (2) the visual problems associated with the 
different syndromes, (3) the usefulness of visual signs and symptoms in differential 
diagnosis, and (4) management and visual care of the patient.  
 
2. Clinical and pathological features of the syndromes  
 
The various Parkinsonism syndromes together with the criteria currently used for their 
diagnosis are listed in Table 1.   
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Table 1. Clinical diagnostic criteria for the Parkinsonism syndromes (CDLB = 
Consortium on dementia with Lewy bodies, NINDS-SPSP = National Institute of 
Neurological Disorders and Stroke and the Society of progressive supranuclear palsy, 
NIH-ORD = National Institute of Health-Office of rare disorders, PD = Parkinson’s 
disease, UK = United Kingdom). 
_____________________________________________________________________ 
Disorder    Diagnostic Criteria  Reference 
_____________________________________________________________________ 
Parkinson’s     Modified UK PD Society Hughes et al.10 
disease     Clinical Diagnostic Criteria 
  
Dementia with Lewy bodies   CDLB     McKeith et al.11 
        
Progressive    NINDS-SPSP    Litvan et al.12,13 
supranuclear palsy       
Multiple system atrophy  Minneapolis Consensus Gilman et al.14  
      Criteria    
Corticobasal degeneration  NIH-ORD    Dickson et al.15 
    
_____________________________________________________________________ 
2.1 Parkinson’s disease (PD) 
 
PD is the most common of the Parkinsonism syndromes throughout the world with the 
possible exception of some oriental countries and in the black population.16 The three 
cardinal signs of PD are akinesia, rigidity, and tremor.17 Akinesia describes the 
characteristic slowness of movement, the initiation of a movement being especially 
affected. Rigidity describes the increase in muscle tone which results in stiffness of the 
limbs and is often manifest as ‘lead-pipe’ or 'cog-wheel’ rigidity. Lead-pipe rigidity 
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refers to the general stiffness of a limb which changes little as the arm is moved whereas 
in cog-wheel rigidity, the arm 'catches' as it moves, as if it were controlled by a cog-
wheel. The patient may also have a ‘blank' facial expression with loss of emotional 
content. Moreover, increased flexion of muscles in the upper back may cause the spine to 
bend forward leading to a characteristic ‘stooped’ appearance. Tremor primarily affects 
the fingers, hands, and head, is most severe while the limb is at rest, and is often 
increased by anxiety but disappears during sleep. In addition, patients treated with 
levodopa (L-dopa) may exhibit ‘dyskinesia’ or ‘dystonia’; in the former the patient may 
fidget, twitch, or be generally restless while the latter describes a spasm of one set of 
muscles deforming a limb into an abnormal posture. 
 
Neuropathologically, the substantia nigra (SN) in the midbrain is particularly affected in 
PD, often being reduced in size as a result of the death of most of its pigmented neurons. 
Cells in the SN project to the striatum via the striatonigral pathway which uses dopamine 
as neurotransmitter. As a consequence, there is decreased connectivity between the SN, 
the globus pallidus, and the subthalamic nucleus.18 This pathway has a general inhibitory 
influence on the striatum and the consequent increased activity of these regions may be 
responsible for the observed tremor and rigidity. In addition, surviving neurons of the SN 
frequently contain inclusions known as ‘Lewy bodies’ (LB) (Fig 1) which are found in 
the cytoplasm of the cell and may be derived from the breakdown products of 
cytoskeletal filaments. LB contain significant amounts of -synuclein,19 a small pre-
synaptic protein which ensures the normal functioning of dopamine transporter and 
tyrosine hydroxylase.20 It normally exists in a relatively unfolded state and is highly 
soluble, but in PD, undergoes a conformational change to insoluble amyloid fibrils.  
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Fig 1. Neuropathology of the substantia nigra in a case of Parkinson’s disease (PD) 
showing the presence of darkly stained Lewy bodies (LB) in many of the surviving 
neurons, (-synuclein immunohistochemistry, haematoxylin stain, magnification bar = 25 
m) 
 
2.2 Dementia with Lewy bodies (DLB) 
 
In DLB11,21 a progressive mental impairment is characteristic, typical features including 
fluctuating cognition, visual hallucinations, and Parkinsonism.11 A prominent and 
persistent memory impairment may not occur in the early stages, but is evident at some 
stage of the disease. Problems of attention and in visuo-spatial ability are common, the 
latter causing difficulties in drawing the shapes of common objects. The majority of 
patients with DLB exhibit at least two of the following features11: (1) fluctuating 
cognitive ability with variation in attention and alertness, (2) frequent visual 
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hallucinations, and (3) the motor features of PD.22 Hence, typical PD features of DLB 
include shuffling gait, reduced arm-swinging while walking, blank expression, rigidity, 
‘ratchet-like’ cogwheeling movements, low speech volume, and difficulties in 
swallowing. There may be two distinct clinical DLB syndromes: (1) DLB and dementia 
accompanied by Parkinsonism with prominent hallucinations and rapid eye movement 
(REM) sleep behavioral disorder, and (2) DLB with ‘Parkinsonism dementia syndrome’ 
in which the symptoms of parkinsonism and dementia predominate.23 
 
Neuropathologically, brain atrophy in DLB resembles that of Alzheimer’s disease (AD)24 
but the size of the parietal, frontal, and temporal lobes is often intermediate between 
those of AD and control brain.25 In the cerebral cortex, areas of temporal lobe such as the 
superior temporal gyrus and parahippocampal gyrus are affected together with the limbic 
system including the hippocampus and amygdala. Other cortical regions involved include 
the cingulate gyrus, insula, claustrum, superior frontal cortex, and occipital cortex. 
Within the basal ganglia, the putamen and caudate nucleus are affected but the globus 
pallidus appears to be relatively unimpaired.26,27 The essential feature necessary for a 
neuropathological diagnosis of DLB is the presence of LB which have a different 
distribution in the brain in DLB compared with PD. Hence, in DLB, there are significant 
numbers of LB in the cerebral cortex whereas in PD, they are largely confined to the SN 
unless a significant dementia is present. LB are also frequent in the insula while fewer 
have been recorded in the frontal, parietal, and occipital regions.28 
 
2.3 Progressive supranuclear palsy (PSP) 
 
PSP, first described in 1964, is significantly rarer than PD, and was originally referred to 
as ‘Steele-Richardson-Olszewski’ syndrome.29 PSP is a complex disorder in which 
clinical progression can vary markedly among patients.30 The most characteristic 
symptoms include gait and balance problems, the patient walking clumsily, and often 
falling backwards. There may also be changes in personality and loss of interest in the 
ordinary activities of life, the patient tiring easily, becoming forgetful, and often losing 
emotional control. With time, controlling the movement of the eyes and eyelids may 
  
10 
become difficult, speech may become slurred, and the patient may find it increasingly 
difficult to swallow solid food or liquid. A small number of patients develop dementia 
which is often associated with the spread of pathological changes to affect the cerebral 
cortex.31 
  
 
Fig 2. Neuropathology of the oculomotor nucleus in a case of progressive supranuclear 
palsy (PSP) showing the presence of darkly stained neurofibrillary tangles (NFT) in many 
of the surviving neurons, Tau immunohistochemistry, haematoxylin stain, magnification 
bar =10 m) 
 
Neuropathologically, the brain of a patient with PSP may show only minor abnormalities 
and is often normal in appearance. Nevertheless, brain weight may be reduced to some 
extent and the midbrain may appear shrunken and atrophic. When the midbrain is 
sectioned, the SN and red nuclei may appear discolored. The volume of the right head of 
the caudate nucleus may be lower in PSP32 and there is often a marked atrophy of the 
globus pallidus.33 In the cerebellum, the superior peduncles and the dentate nuclei may be 
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reduced in size and the hillus discolored. Histologically, there is loss of neurons, 
proliferation of glial cells, the presence of inclusions in the cytoplasm of neurons termed 
neurofibrillary tangles (NFT) (Fig 2), the appearance of intracellular vacuoles, and loss of 
myelin, the globus pallidus, subthalamic nucleus, and SN being particularly affected.34 
The most significant molecular constituent of the NFT is the microtubule associated 
protein (MAP) tau which is involved in the assembly and stabilization of microtubules. In 
normal neurons, tau is soluble and binds reversibly to microtubules with a rapid 
turnover.35 In disorders such as PSP, however, tau does not bind to the microtubules but 
collects as insoluble aggregates as paired helical filaments (PHF) which resist proteolysis 
and ultimately accumulate as NFT.  
 
2.4 Multiple system atrophy (MSA) 
 
MSA is derived from three previously described syndromes: (1) olivo-pontocerebellar 
atrophy, (2) striato-nigral degeneration, and (3) Shy-Drager syndrome.36 A variety of 
signs and symptoms are present including autonomic failure, Parkinsonism, cerebellar 
ataxia, and pyramidal signs such as paralysis, muscle weakness, loss of muscle control, 
and tremor. The most consistent clinical syndrome, however, is Parkinsonism, followed 
by autonomic dysfunction, cerebellar ataxia, and pyramidal tract signs.37 Urinary 
dysfunction is the most common autonomic symptom and an earlier manifestation of the 
disease than postural low blood pressure. Patients with either cerebellar signs or 
Parkinsonism may be distinct subtypes of the disease, viz. MSA-C and MSA-P 
respectively. MSA-C patients have marginally increased survival times but the prognosis 
is poor for the majority. In addition, patients with MSA-P may have abnormal 
movements of the hands and fingers referred to as a ‘jerky’ tremor or myoclonus, no 
abnormal movements being present at rest but when holding a posture, small amplitude, 
non-rhythmic movements of one or a few fingers may occur. There is a moderate 
intellectual impairment in some patients but overt dementia is relatively rare.37  
 
Neuropathologically, the cerebral cortex in MSA is smaller than in controls, the degree of 
atrophy reflecting disease duration rather than the age of the patient.38 In addition, there 
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may be a progressive cerebral atrophy affecting the frontal lobes39 and the 
motor/premotor areas. In the cerebellum, a more severe pathology affects the vermis than 
the hemispheres.40 Within the basal ganglia, the SN is often pale due to loss of pigment 
and there may be atrophy and discoloration of the striatum, specifically affecting the 
putamen. Histologically, MSA is characterized by neuronal loss, gliosis, and myelin 
pathology in the putamen, caudate nucleus, external pallidum, substantia nigra, locus 
caeruleus, inferior olive, pontine nuclei, Purkinje cells of the cerebellum, and the 
intermediate cell columns of the spinal cord.37,41 The most characteristic pathological 
change is the presence of glial cytoplasmic inclusions (GCI) in oligodendrocytes, a 
pathology first described in 1989.42 This change often affects the SN, striatum, inferior 
olivary nucleus, pontine nuclei, and cerebellum.42 Inclusions have also been observed in 
the nuclei, cytoplasm, and cell processes of neurons in MSA.43  
 
2.5 Corticobasal degeneration (CBD) 
 
CBD is a rare, progressive disorder with a disease onset usually after 60 years of age, 
death following within approximately eight years. Clinical diagnosis can be complex as 
symptoms may resemble other types of neurodegenerative disorder. The most 
characteristic clinical features are limb dysfunction44,45, parkinsonism,46 apraxia,45 and 
dementia.46 Onset of symptoms can be sudden,47 patients exhibiting problems related to 
cortical processing and motor dysfunction, the most common initial symptom being limb 
clumsiness affecting one side of the body with or without accompanying rigidity or 
tremor.44,48 Subsequently, the disease may progress to affect gait and there is a slow 
progression to affect the ipsilateral arms and legs.44 Apraxia and cortical dementia are the 
most common cortical signs.48  
 
Neuropathologically, CBD is characterized by a progressive and often asymmetric 
cortical atrophy which affects the anterior cerebral cortex,49 the fronto-parietal region,50 
and the superior temporal cortex.50 Atrophy of the basal ganglia, including the caudate 
nucleus51 and SN is common52 accompanied by a mild to moderate gliosis and neuronal 
loss in the putamen, globus pallidus and subthalamic nucleus.53 The typical gross features 
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of the brain include enlarged lateral ventricles and atrophy of the head of the caudate 
nucleus, while the internal capsule, insula, putamen, and globus pallidus are more normal 
(Fig 3). Histologically, there is a widespread neuronal and glial pathology including 
abnormally enlarged neurons.54 neuropil threads55 NFT,50 and glial pathology. The glial 
pathology includes oligodendroglial inclusions56 and astrocytic plaques which largely 
affect the caudate nucleus.57 In the cortex, these lesions are particularly severe in the 
posterior frontal area anterior to the precentral gyrus but are less severe in the primary 
motor area.49  
 
 
 
Fig 3. Coronal section of the striatum of the brain from a pathologically confirmed case 
of corticobasal degeneration (CBD). The figure shows enlarged lateral ventricles (LV), 
atrophy of the head of the caudate nucleus (CN), but more normal internal capsule (IC), 
external capsule (EC), claustrum (Cl), and putamen (PuT) (bar = 4 mm).  
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3. Visual problems in the Parkinsonism syndromes  
 
For the purpose of this discussion, aspects of visual function in the Parkinsonism 
syndromes have been divided into various categories based largely on those used to 
characterize vision in the dementias58 and are summarized in Table 2. Although these 
aspects of vision are discussed individually, many patients exhibit multiple visual defects. 
In addition, a number of factors need to be taken into account in interpreting these 
observations. First, some aspects of visual function have been little studied making a 
comparison problematical. Second, most studies rely on a clinical diagnosis of a 
syndrome and therefore, on the criteria used and should be viewed with caution if the 
most rigorous consensus criteria have not been applied. Third, visual testing may be 
carried out using a variety of different objective and subjective methods and the 
effectiveness of some of these methods in testing participants, especially if dementia is 
present, should be taken into account. Fourth, participants may have been visually 
assessed without having had an eye examination, and thus, without knowing if the 
optimal refraction has been used or if an ocular pathology was present.58 
 
4.1 Visual acuity (VA) 
 
Patients with a Parkinsonism syndrome frequently exhibit poor vision, especially in PD 
as the disease progresses and if dementia is present.59,60 Poor VA is particularly evident if 
low contrast stimuli are used.61,62 In addition, poor VA may be associated with the 
development of chronic hallucinations which are especially frequent in PD and DLB.63 
Primary aspects of vision have been less well studied in the other Parkinsonism 
syndromes but defects in VA are likely to occur in DLB and PSP.59 In CBD, in which 
difficulties involving visuospatial tasks or in reading ability have been reported, the 
patients denied that they had a significant visual loss.64 
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Table 2. Comparison of visual problems among Parkinsonism syndromes.  
      
Syndrome 
_____________________________________________________________________ 
Feature    PD DLB PSP MSA CBD 
_____________________________________________________________________ 
Visual acuity    ++ + + ? ? 
Color vision    + + - + -   
Stereopsis    + ? ? ? ?  
Contrast sensitivity   + ? + - ? 
Visual fields    +g,s + ? ? ++ 
Eyelid mobility   ? ? + ? + 
Pupil response to mydriatics  + + + ? ? 
Abnormal pupils   ? ? + + ? 
Blink frequency   + ? ? ? ?   
Blink reflex    + + ? + + 
Blepharospasm   ? ? ++ ++ +   
Fixation    - ? + + +  
SEM     + +c + + +  
SPM     + ? + + + 
VSP     - ? ++ - - 
Nystagmus    ? ? + ? +  
VOR     - ? + + - 
EEG     +θ ? + ? +.fs  
ERG     +f +f + - ? 
VEP     + ? - V ?   
ERP     ? + + +ch + 
Discrimination   ? ++ ? ? ?  
Visuo-spatial function  + + ? ? ++  
Speech, Language   + ? + + ?  
Visual hallucinations   ++ ++ - ? - 
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REM sleep disorder   + + + + -   
_____________________________________________________________________ 
Abbreviations: Syndromes: PD = Parkinson’s disease, DLB = Dementia with Lewy 
bodies, PSP = Progressive supranuclear palsy, MSA = Multiple system atrophy, CBD = 
Corticobasal degeneration. Visual features: EEG = Electroencephalogram, ERG = 
Electroretinogram, ERP = Event-related potential, SEM = Saccadic eye movements, SPM 
= Smooth pursuit movements, VEP = Visual evoked potential, VOR = Vestibulo-ocular 
reflex, VSP =   Vertical supranuclear gaze palsy; Response: Unaffected (-), Significantly 
affected (++), Affected (+), Not affected (-), Variable (V), Data limited or controversial 
(?). Superscripts: c = complex stimuli,  = delta waves, Ch = Chromatic VEP, f = Flash 
VEP, fs = focal slow waves, g = glaucoma, s = surgery, θ = theta waves.  
 
4.2 Color vision 
 
In PD, vision may also be blurred using colored stimuli65 with reduced color flicker 
fusion times66 accompanied by a progressive deterioration of the ability to discriminate 
among colors.67 In the early stages of PD, however, color vision discrimination may not 
be consistently impaired as measured using the Farnsworth-Munsell 100-hue test.68 There 
is also evidence that color vision problems may be more characteristic of disorders which 
have a molecular pathology based on -synuclein, i.e., PD, DLB, and MSA, rather than 
those disorders which have a tau pathology, i.e., PSP and CBD.69 
 
4.3 Stereopsis 
 
Stereopsis or ‘binocular depth perception’ involves various neural pathways involving the 
thalamus and posterior parietal lobe. In PD patients with poor VA, there may be defects 
in stereopsis as measured by random dot stereograms70,71 and these problems are often 
associated with impaired color perception, and attributable to pathology in extrastriate 
visual cortical areas.72 Stereopsis remains a poorly investigated aspect of vision in other 
Parkinsonism disorders. 
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4.4 Contrast sensitivity (CS) 
 
Contrast sensitivity (CS) is a measure of visual performance across a wide range of 
spatial frequencies and contrasts. In PD, for example, CS is affected in some patients,73,74 
performance at high or intermediate frequencies being the most reduced thus providing 
one possible explanation for their poor vision. A substantial decrease in CS may also 
occur with disease progression. Abnormalities of CS in PD may be related to dopamine 
dysfunction in the retina but are also orientation specific which suggests cortical 
involvement.75 Furthermore, treatment with L-dopa may improve CS performance in PD 
close to that of controls.76 There have been few psychophysical studies carried out on 
other types of Parkinsonism but patients with PSP have been shown to exhibit impaired 
CS, an effect that may be less apparent in MSA.77 
 
4.5 Visual fields 
 
Relatively few detailed studies of visual fields have been carried out to date in any 
Parkinsonism syndrome.78 Nevertheless, there may be an increased frequency of visual 
field defects in PD if glaucoma is present.79 Visual fields have also been investigated in 
PD patients undergoing posterior pallidotomy, a surgical procedure which may damage 
the optic tract.80 Forty such patients were studied, three having visual field defects which 
could have been attributable to the surgery, viz., contralateral superior quadrantanopia, 
associated in two patients with small paracentral scotomas. In DLB, a 66 year-old patient 
developed a left homonymous hemianopia early in the disease and had large numbers of 
LB in the visual cortex.81 In addition, studies of regional cerebral blood flow (rCBF) in 
DLB indicated hypoperfusion in occipital cortical areas which could result in visual field 
loss.82 The highly lateralized pathology often present in CBD suggests that a hemianopia 
may be more common in this disorder than in other syndromes. A rare case of MSA has 
also been reported with enlarged blind spots but with no central scotoma.83 
 
4.6 Eyelids 
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A disorder of eyelid mobility has been observed in approximately a third of PSP 
patients84 with both spontaneous and voluntary eye movements affected.85 Since ocular 
and eyelid movements are highly coordinated mainly in the vertical plane, vertical 
supranuclear gaze palsy (VSP) is often regarded as a cardinal feature of PSP.84  Eyelid 
reflexes are generally preserved with the exception of the ‘acoustic startle reflex’, which 
is a response to a sudden and unexpected sound involving a brief closing of the eye. 
Eyelid problems in PSP can also seriously impair vision as a result of difficulties in 
opening the eyes after voluntary closure (‘apraxia of eye opening’). This problem is 
likely to be attributable to a loss of the reciprocal relationship between the levator 
palpebrae and the pretarsal portion of the orbicularis oculi muscles both of which contract 
together rather than exhibiting a normal opponent action.86 Apraxia of eyelid opening has 
also been observed in CBD.86 
 
4.7 Blinking and the blink reflex  
 
Patients with PD exhibit a reduced frequency of blinking leading to a staring 
appearance.87 Reduced blink rates can cause an abnormal tear film, dry eye, and reduced 
vision. In addition, blink duration may be increased in PD reflecting the loss of dopamine 
neurons.88  
 
The blink reflex is elicited by a light tap on the glabella, successive taps in normal 
individuals producing less and less response as the reflex habituates. In PD, for example, 
the blink reflex may not disappear on repeated tapping. The blink reflex to electrical 
stimulation of the supraorbital nerve has been studied in the Parkinsonism syndromes 
including patients with DLB.89 The reflex was significantly delayed in DLB compared 
with controls and the other syndromes, with a bilateral delay in the latency of the R2 
response. In a proportion of DLB, patients, the latency delay was greater than two 
standard deviations of the control mean.  There was also a significant correlation between 
the delay in the R2 response and the degree of cognitive fluctuation of the patient. In 
addition, the blink reflex was studied in DLB patients treated with cholinesterase 
inhibitors.90 Treatment with donepezil was not associated with a change in cognitive or 
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motor performance but after two weeks of treatment, the latency of the R2 response was 
significantly decreased. In a 65-year-old female patient with MSA, blink reflexes were 
poor with an impaired R2 response and enhanced recovery cycle which could be 
attributable to increased excitability of brain stem interneurons.91 In a single case 
diagnosed as severe CBD, the blink reflex was completely absent.92 
 
‘Blepharospasm’, an abnormal contraction or twitch of an eyelid, is a common symptom 
and when observed early in untreated patients with Parkinsonism should raise a suspicion 
of the presence of MSA, PSP, or CBD.93 In addition, blepharospasm may be more 
prevalent in PSP and MSA than in the other Parkinsonism syndromes.94,95 
  
4.8 Pupillary function 
 
Abnormal pupillary responses have been reported to the mydriatic muscarinic receptor 
antagonist tropicamide in a variety of disorders but remain controversial. The earliest 
reports suggest some patients with AD, for example, displayed a specific response to a 
low dose (0.01%) of tropicamide, pupils dilating by approximately 13% or more 
compared with controls.96 Later studies, however, suggested there were no difference in 
the pupillary responses of AD patients when compared with several other disorders 
including PD.97 In PSP, studies suggest that the results of the tropicamide test may also 
be similar to those observed in patients with AD.98 Enhanced pupillary responses have 
also been reported using dilute solutions of phenylephrine (a sympathetic agonist) and 
pilocarpine (a cholinergic agonist).99 Hence, response to a 0.065% solution of pilocarpine 
was studied in DLB, pupil responses being significantly greater in DLB than in AD.  
 
Some authors report decreased pupil diameters in the dark in PSP compared with 
controls.100 In MSA, about a quarter of patients tested had abnormal pupils and in the 
majority, the defects were bilateral and symmetrical. Pupil defects were not usually 
apparent to the patients themselves or to their physicians. In addition, in normal subjects, 
pupil size often increases in response to stress but no such change is apparent in MSA.101 
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‘Horner’s syndrome’ (abnormally small pupil diameter) has rarely been observed, 
although such a change has been reported in one case of MSA.102 
 
4.9 Fixation 
 
Normally the eyes will turn inwards when fixating a near target (‘convergence’). 
Abnormal ocular fixation, however, has been shown in a study of seven out of eight 
patients with PSP,103 individuals demonstrating a ‘fixation instability’ accompanied by 
small side to side movements of the head (‘square wave jerks’).104 This type of response 
is relatively rare in PD.103 In addition, patients with PSP exhibit ‘heterophoria’, i.e., a 
tendency for the eyes not to line up properly when one eye is covered.105 As a result, 
patients often exhibit difficulties in making eye contact and develop a ‘staring 
appearance’ similar to that in PD. Abnormal ocular fixation may also occur in a 
significant proportion of MSA patients.36 Convergence problems can be associated with a 
relatively large exophoria (deviation of an eye outwards), and the result is often 
diplopia.106 
 
4.10 Eye movement  
 
Abnormal saccadic (SEM) and smooth pursuit eye movements (SPM), usually studied by 
clinical examination in combination with electrooculography (EOG), have been reported 
in about 75% of patients with PD.107 Both reaction time and the maximum saccadic 
velocity of horizontal gaze are slower in PD,107 but the response of PD and controls 
frequently overlap.108 In addition, SEM may exhibit hypometria (‘under reaching of 
task’)109 while SPM may be interrupted by small saccades.106 The amplitude of SEM is 
often increased in normal subjects when there is a change from externally cued saccades 
to self-paced saccades and this effect may be enhanced in PD.110 In addition, patients 
with PD often have difficulty in sustaining repetitive actions and hence, SPM my exhibit 
reduced amplitudes and a progressive decline as the stimulus is repeated.111 Abnormal 
optokinetic nystagmus (AON)107 and problems in convergence112 have also been reported 
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in PD. Further abnormalities include 'jerkiness', 'cogwheeling', and limitation of eye 
movement. Vertical eye movements are often more impaired than horizontal movements.  
 
A comparison of SEM in DLB and in PD with dementia suggests that DLB patients were 
impaired in both reflexive and saccadic execution and in the performance of more 
complex SEM tasks.113 In addition, problems in convergence were often followed by 
akinesia and rigidity.114 Some cases of DLB can also present with a vertical and 
horizontal gaze palsy and these could be easily confused with PSP115 and caution is 
therefore necessary in distinguishing the two disorders.116 
 
VSP is often regarded as a ‘cardinal’ sign of PSP.84,117 As the disease progresses, 
however, upgaze may also be affected and eventually, a complete gaze palsy may occur 
resulting in diplopia.118 In addition, PSP patients exhibit slow SEM,117 a significantly 
decreased ability to carry out vertical saccades, and an early slowing of horizontal 
saccades.119 A reduction in the generation of motor commands by midbrain ‘burst’ 
neurons may be the most likely explanation for slower saccades in PSP.120 As a 
consequence, additional SEM are often necessary for PSP patients to achieve fixation 
especially in the vertical plane.121 SPM may also be affected in PSP,117 the median gain 
of the movements being less than in controls122 and small corrective saccades may be 
necessary for the eyes to fixate their target. SPM involve several brain areas including the 
parietal and occipital cortices, the frontal eye-fields, the cerebellum, as well as nuclei in 
the basal area of the pons.123 AON has also been reported in PSP, vertical responses 
including an impaired slow phase response while the rapid phase is combined with the 
appearance of square-wave jerks.124 
 
In a patient with MSA, in which a combination of olivopontocerebellar atrophy and 
striato-nigral degeneration was present, the typical eye movement impairments 
characteristic of PD were observed, in combination with AON in the vertical plane.125 
SEM and SPM in the vertical direction, however, were only slightly affected. In a study 
of oculomotor function in thirty MSA patients, excessive square-wave jerks, a mild 
supranuclear gaze palsy, a gaze-evoked nystagmus, a positioning down-beat nystagmus, 
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mild-moderate saccadic hypometria, impaired SPM, and reduced vestibulo-ocular reflex 
(VOR) suppression were all present in a significant number of the patients.126 
 
In CBD, an increase in saccadic latency may be a characteristic feature.119,127,128 Hence, 
in a study of 36 well-characterized CBD patients, SPM were commonly affected, a 
significant number of patients presenting with ‘jerky’ movements, and in a small number 
of these patients, the range of movement was also restricted.44 Decreased gain of SPM 
has also been observed in CBD129 as well as square-wave jerks44,130 while AON may also 
be common.64 
 
4.11 Vestibulo-ocular reflex (VOR) 
 
The vestibulo-ocular reflex (VOR) is a reflex eye movement that stabilizes images on the 
retina during movements of the head. The ‘gain’ of the VOR is the ratio of the change in 
eye angle to head angle during a head turn. If the gain is impaired (ratio not equal to 
unity), head movements result in image motion on the retina and blurred vision. The gain 
of the VOR in the dark may be cancelled by fixation. Both MSA and PSP patients show 
this cancellation compared with control cases and PD,77 a response which could be 
related to cerebellar dysfunction. In CBD, in which there is a less significant cerebellar 
pathology, there is little evidence for an effect on VOR. 
 
4.12 Electroencephalogram (EEG) 
 
Electroencephalography (EEG) has been performed in response to eye opening and to 12-
Hz photic stimulation in PD using global field synchronization (GFS), which assesses the 
degree of correlation between waves of different frequency.131 However, closing the eyes 
resulted in an increase in theta-GFS while using 12-Hz intermittent photic stimulation, 
reactivity of posterior electrodes was decreased indicating a general disruption of 
posterior brain activity.131 In addition, a slowing of general background activity and the 
appearance of focal slow waves (FSW) has been reported in CBD.132 Intermittent delta 
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activity has also been recorded in both CBD and PSP, but FSW may be characteristic 
only of CBD.132 
 
4.13 Electroretinogram (ERG) 
 
ERG using a flash stimulus has been studied in PD and DLB compared with controls,133 
abnormalities being recorded in both disorders and attributed to pathology affecting 
photoreceptor cells and the inner plexiform layer. In PSP, the amplitude of the ERG may 
be reduced134 as well as that of the electromyogram (EMG) recorded from the orbicularis 
oculi muscle. The pattern reversal ERG (PERG) to a colored stimulus was recorded in 
both PD and MSA.135 Although reduced amplitude and increased latency of evoked 
components were observed in PD, especially when a blue-yellow horizontal grating was 
used as a stimulus, no significant effects were present in MSA.135  
 
4.14 Visual evoked potentials (VEP) 
 
Longer latencies of VEP components have been observed in PD, the extent of the delay 
being correlated with the severity of motor symptoms.136 Latencies are often longer when 
colored stimuli are used especially with a blue-yellow grating.135 Early signal 
components of the VEP, such as the P100, are usually not affected in PSP.137 In MSA, 
VEP responses are more variable with significantly less impairment to a full-field flash 
stimulus than in PD or PSP.134 Moreover, using a horizontal sinusoidal grating, no effects 
on the VEP in MSA were reported although such effects were recorded in PD.138  
 
4.15 Event-related potentials (ERP) 
 
Event-related potentials (ERP) elicit the ‘P3’ (P300) evoked response which reflects 
orientation, attention, stimulus evaluation, and memory. Mean latency of the visual P200 
and P300 ERP responses are greater in DLB than in controls suggesting that visual 
cognitive function may be selectively impaired. The latency and amplitude of the P300 
signal, however, are also affected in PSP.138-142 In MSA, the visual P300 component can 
  
24 
be successfully recorded even when a severe motor disability was present.141 Reaction 
times to rare target stimuli were also significantly decreased in both PD and MSA 
compared with PSP.142 In addition, ERP has been studied in MSA-C and MSA-P, no 
significant differences being observed between subtypes in the latency of the N1 or N2 
components suggesting early stages of visual processing were preserved.143 Nevertheless, 
the P3a peak was less easy to identify and there were some reductions in amplitude of 
this response in both MSA subtypes. By contrast, the P3b component appeared to be 
affected only in the MSA-C subtype and exhibited both increased latency and reduced 
amplitude. In a further study of selective attention to color in MSA,144 the N2 component 
was significantly delayed suggesting that the color discrimination process may be 
impaired during selective attention in MSA. In CBD, the latency of the visual P300 was 
increased and mean reaction times were greater in both CBD and in PSP compared with 
PD, the degree of the response being correlated with the extent of motor disability.142 
 
4.16 Complex visual functions 
 
More complex visual problems are frequent in the Parkinsonism syndromes and may 
involve reading ability, visuo-spatial function, and in the identification and naming of 
objects. In DLB, for example, impairments have been identified in object size 
discrimination, form discrimination, overlapping figure identification, in drawing 
common objects, and in tasks involving visual counting.145 By comparison, performance 
on line orientation, color integration, and rotated object comparison tasks appeared less 
affected.146 A significant defect in the ‘trail-making task’, a test of visual attention in 
which the subject is asked to ‘connect the dots’ on paper or computer screen, has also 
been reported in DLB.147 
 
Deficits in visuo-spatial function including difficulty in judging verticals and the position 
of body parts, and in carrying out a route-walking task have been reported in both PD and 
DLB.148,149 Hence, inability to copy the shape of a pentagon may be more evident in DLB 
than in AD suggesting a greater visuospatial deficit.150 Moreover, PD and DLB patients 
may have a problem in memory tasks which involve spatial orientation, PD patients in 
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particular exhibiting an impairment of orientation and motion discrimination.151 Problems 
involving the perception and imagining of faces has also been reported in PD,152 most 
frequently in untreated patients.153 Moreover, controls often contract their facial muscles 
while imaging faces, a process which can be impaired in PD, and which may be related to 
pathological changes affecting the basal ganglia.154 
 
Patients with a Parkinsonism syndrome often exhibit problems with speech, language, 
and reading especially in PD, PSP, and MSA,155,156 similar reductions in reading speed 
being present in all three syndromes. In addition, PSP patients may exhibit dysarthria, 
reading difficulties, and problems with handwriting.155 Some PSP patients also exhibit 
visual dyslexia, constructional dysgraphia, and an increased rate of self-correction. Visual 
misperception was a major cause of problems in naming objects in these patients. 
 
In a case of ‘atypical CBD’, a patient exhibited a decline in spatial orientation and visual 
function which included fixation, optic ataxia, agraphia, acalculia, ideomotor apraxia, but 
color matching ability was preserved.157 CBD patients may also exhibit difficulties in 
locating objects within visual space,64 visuo-spatial problems in CBD appearing to be 
more severe when spatial rather than object-based tasks are involved.158 These problems 
could be related to pathology affecting the frontal region of the brain159 and the visual 
association areas in CBD.160 
 
4.17 Visual hallucinations 
 
Visual hallucinations are commonly reported in the Parkinsonism syndromes, especially 
in those individuals with impaired VA or who have more severe cognitive 
impairments.161 Nevertheless, hallucinations are generally more common in DLB and 
PD162 than in PSP or CBD.163 Visual hallucinations in DLB are frequently recurrent, 
well-formed and detailed.164 They most typically involve people or animals invading the 
patient’s home, but may also include inanimate objects, such as the appearance of writing 
on walls or ceilings. The hallucinations do not appear to trouble the majority of patients 
but can evoke considerable fear in some.164 Visual hallucinations also occur as a 
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complication in about 30 - 60% of PD patients treated with L-dopa and dopamine 
agonists.165 These hallucinations may be particularly complex with flickering lights and 
illusionary misconceptions followed by colorful images. Poor VA and reduced activity of 
the primary visual cortex (area V1) may be risk factors the development of visual 
hallucinations. 
 
4.18 REM sleep behavioral disorder 
 
Various disorders involving sleep, including excessive daytime sleeping, have been 
reported in the Parkinsonism syndromes.166 However, REM sleep behavior disorder 
appears to be the most characteristic symptom having been observed in many of the 
disorders and characterized by abnormal behavior during sleep accompanied by REM.167 
So common is REM in Parkinsonism that it is often regarded as a strong indicator of the 
presence of such a syndrome. Nevertheless, REM sleep behavior disorder appears to be 
rarer in CBD, recent estimates suggesting an incidence of only 5%, and its absence could 
be a useful additional diagnostic feature.168 
 
5. Discussion and conclusions 
 
5.1 Visual features of the Parkinsonism syndromes 
 
Visual problems in the Parkinsonism syndromes can be highly variable with some 
patients being visually asymptomatic whereas others exhibit one or more visual 
problems. Visual dysfunction may involve a variety of ocular structures and affect many 
functions including VA, CS, color discrimination, pupil reactivity, eye movements, visual 
field defects, and visual processing speeds. In addition, disturbance of visuo-spatial 
orientation, facial recognition problems, REM sleep behavior disorder, and chronic visual 
hallucinations may occur. Some of these visual features may be characteristic of the early 
stages of a Parkinsonism syndrome including problems in pupil reactivity169 SPM,170 
visuo-motor adaptation,171 and sleep behavior disorder. The presence of any of these 
features in undiagnosed individuals may raise a concern of a possible Parkinsonism 
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syndrome, and since early diagnosis may enable intervention and possible 
neuroprotection,172 further visual studies of early-stage symptoms in the Parkinsonism 
syndromes are indicated.  
 
5.2 Differential diagnosis of Parkinsonism syndromes 
  
Some of the visual features described in the Parkinsonism syndromes have been little 
investigated, e.g. stereopsis and CS whereas others may occur in all disorders and have 
little diagnostic value, e.g., VA and some aspects of eye movement. In addition, there are 
few visual features that will affect all patients with a specific syndrome. Nevertheless, 
there are some visual features which in combination with other signs and symptoms may 
be useful in a differential diagnosis (Table 3). Two features in particular may enable an 
initial separation of the Parkinsonism syndromes into two groups. First, the presence of 
visual hallucinations may indicate an underlying -synuclein-type pathology in some 
disorders, i.e., supporting a diagnosis of PD or DLB rather than PSP or CBD.173 
However, MSA which is also has -synuclein pathology may be an exception to this rule. 
Second, color vision problems may be more characteristic of the -synuclein than the 
tau-based disorders.69  
 
In addition, there may be combinations of visual features which may be helpful in 
separating specific pairs of disorders. Hence, distinguishing PD and PSP can be 
especially difficult especially early in the disease. Atypical features of PSP include 
slowing of upward saccades, moderate slowing of downward saccades, the presence of a 
full range of voluntary vertical eye movements, a curved trajectory of oblique saccades, 
and absence of square-wave jerks.174 Especially useful in separating PSP from other 
disorders is the presence in the former of vertical supranuclear gaze palsy, fixation 
instability, lid retraction, blepharospasm, and apraxia of eyelid opening and closing.104 
Vertical supranuclear palsy is probably the single most useful diagnostic clinical sign of 
PSP84]although such signs do occur more rarely in other disorders.115,116 
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Table 3. Potentially useful visual motor and non-motor features that may help in 
distinguishing the Parkinsonism syndromes. 
     
Visual features  
_____________________________________________________________________ 
Disorder  Motor     Non-motor 
_____________________________________________________________________ 
PD   Slower reaction time and  Color vision deficits, 
   velocity of saccades,    visual hallucinations, 
   hypometria, SPM affected  PERG affected 
   early 
 
DLB   Impaired performance of  Color vision deficits, 
   more complex eye movement  visual hallucinations 
   tasks 
 
PSP   Vertical supranuclear gaze  Contrast perception 
   palsy, fixation instability, lid   affected, P300 ERP 
   retraction, blepharospasm, apraxia affected 
   of eyelid opening and closing 
 
MSA   Abnormal fixation, square wave Color vision deficits 
   jerks, mild supranuclear gaze  less frequent, PERG less  
   palsy, gaze evoked nystagmus,  affected 
   saccadic hypometria, down-beat 
   nystagmus, impaired SPM,  
   reduced VOR suppression 
 
CBD   Increase in saccadic latency.  Visual field defects  
   ‘jerky’ SPM, square-wave jerks, likely, visuo-spatial 
   optokinetic nystagmus  problems, P300 ERP 
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        affected, REM sleep  
        less affected 
_____________________________________________________________________ 
Abbreviations: Disorders: PD = Parkinson’s disease without dementia, DLB = Dementia 
with Lewy bodies, PSP = Progressive supranuclear palsy, CBD = Corticobasal 
degeneration; MSA = Multiple system atrophy, Visual features: ERP = Event-related 
potential, SPM = smooth pursuit eye movements, PERG = Color electroretinogram, REM 
= Rapid eye movement, VOR = Vestibulo-ocular reflex  
 
Separating PD from DLB can be difficult especially if dementia is present. Nevertheless, 
the distinction is important because patients with visual hallucinations may be treated 
with antipsychotic drugs, a hazardous treatment in DLB.175 DLB and PD generally 
exhibit similarities on SEM tasks. Nevertheless, a newly developed portable 
saccadometer, has been used to compare Parkinsonism syndromes176 and suggests that a 
combination of saccadic parameters may enable PD and DLB to be separated. In 
addition, deficits in orientation, ‘trail-making’, and reading the names of colors (‘Stroop 
test’) may indicate DLB rather than PD.147  
 
A number of visual symptoms may be suggestive of MSA including excessive square-
wave jerks, mild to moderate hypometria of saccades, impaired VOR, and the presence of 
nystagmus.126 Visual hallucinations, unrelated to medication, are also rare in MSA 
compared with PD.177 Moreover, the color VEP is affected in PD but not in MSA.135 An 
additional feature which may be useful in separating PD and MSA is an ability to fixate 
an object, which is abnormal in a significant proportion of patients with MSA but less so 
in PD.103 In addition, eye movements recorded during sinusoidal tracking by EOG show 
that in MSA, saccades may correct for position errors (‘catch-up saccades’) while in PD, 
saccades are directed towards future target positions (‘anticipatory saccades’).178 
 
CBD is a particularly complex disorder and distinguishing it from other Parkinsonism 
syndromes can be challenging.45,48 Nevertheless, a combination of increased latency of 
SEM,119,127,128 impaired SPM,44 and visuo-spatial problems especially involving object-
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based tasks145 may be more typical of CBD while vertical gaze palsy, visual 
hallucinations, sleep disturbance, and an impaired ERG are relatively rare.  
 
5.3 Visual Management of the patient 
 
Visual symptoms in the Parkinsonism syndromes when present are important in 
influencing overall motor function and can be markedly debilitating when a combination 
of visual deficits are present.64 Hence, identifying and correcting visual problems as far 
as possible can reduce the chances that a patient may have a serious fall and can be 
important in improving QOL. A multidisciplinary approach is often necessary to manage 
the problems of the patient including pharmacological intervention and rehabilitation.179 
 
Collaboration between the patient, eye-care practitioners, and various health care 
providers is important in identifying and managing specific visual problems. First, a 
decline in VA is fairly typical of the Parkinsonism syndromes in general. Appropriate 
refractive correction can improve overall motor performance and associated procedures 
such as cataract surgery may help to maximize vision.  Second, visual fields should be 
tested as the pathology may be lateralized resulting in a hemianopia, especially in CBD 
or in PD if there is associated glaucoma.180,181 Third, the external eye should be examined 
as blepharospasm and/or dry eye may be present and are essentially treatable visual 
features.86,93,95 Artificial tears can be used to help dry eyes while blepharospasm has been 
treated successfully with botulinum toxin A injected at the junction of the preseptal and 
pretarsal parts of the levator palpebrae and orbicularis oculi muscles.86 Fourth, patients 
with difficulties in opening their eyelids can have ‘lid crutches’ fitted to spectacle frames 
that can hold the lids open. Fifth, patients may have deficits in gaze control which may 
influence ‘stepping behavior’ thus increasing the risk of trips or falls.182 In addition, 
impaired postural control is common and a significant contributor to falls.183 Balance 
training combined with eye movement and visual awareness exercises may improve gaze 
control in both PSP and may also help in PD. Sixth, patients may have problems locating 
objects in visual space158 and strategies to improve object recognition in the home could 
be beneficial. Seventh there may be a potential problems involving driving in the 
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Parkinsonism syndromes because of low contrast VA deficits, as in PD.184 It is also 
possible that some pharmacological interventions could produce effects on fitness to 
drive.185  
 
In conclusion, visual problems in the Parkinsonism syndromes can involve a variety of 
functions including VA, CS, color discrimination, pupil reactivity, SEM, SPM, visual 
fields, and visual processing speeds. In addition, disturbance of visuo-spatial orientation, 
facial recognition problems, REM sleep behavior disorder, and chronic visual 
hallucinations may be present. Visual dysfunction may provide some useful diagnostic 
features helpful in differentiating the different syndromes, the presence of visual 
hallucinations, color vision problems, visuo-spatial deficits, and variations in eye 
movement problems being possible discriminating features. 
 
References 
 
1. Armstrong RA. Visual signs and symptoms of Parkinson’s disease. Clin Exp Optom 
2008; 91 (2): 129-138. DOI:10.111/j.1444-0938.2007.0021.x 
 
2. Armstrong RA. Visual signs and symptoms of dementia with Lewy bodies. Clin Exp 
Optom 2012; 95 (6): 621-630. DOI:10.1111/j.1444-0938.2012.00770.x 
 
3. Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin 
Exp Optom  2011; 95 (2): 150-160. DOI:10.1111/j.1444-0938.2010.00504.x 
 
4. Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp 
Optom  2014; 97 (6): 483-491. DOI:10.1111/cxo.12206 
 
5. Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp 
Optom  2016; 99 (6): 498-506. DOI:10.1111/cxo.12429 
 
  
32 
6. Antal A, Bandini P, Keri S, Bodis-Wollner I. Visuo cognitive dysfunctions in 
Parkinson’s disease. Clin Neurosci 1998; 5 (2):147-152. 
 
7. Armstrong RA. Oculo-visual dysfunction in Parkinson’s disease. J Park Dis 2015; 5 
(4): 715-726. DOI:10.3233/JPD-150686 
 
8. Earley CJ. Restless legs syndrome. New Eng J Med 2003; 348  (21), 2103-2109. 
DOI:10.1056/NEJMcp021288 
 
9. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy 
body Parkinson’s disease. Neurology 2001, 57 (8), 1497-1499. 
 
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of 
idiopathic Parkinson disease: a clinic-pathological study of 100 cases. J Neurol 
Neurosurg Psy 1992 (3); 55: 181-184. DOI:10.1136/jnnp.55.3.181 
 
11. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, 
Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, 
Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, 
Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and 
pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium 
on DLB international workshop. Neurology 1996; 47 (5): 1113-1124. 
 
12. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Davoisen RC, Goetz CG, Golbe 
LI, Grafman J, Growden JH, Hallett M, Jankovic J, Quinn NP, Tolisa E, Zee DS, Chase 
TW, FitzGibbon EJ, Hall Z, Juncos J, Nelson KB, Oliver E, Pramstaller P, Reich SG, 
Verny M. Clinical research criteria for the diagnosis of progressive supranuclear palsy 
(Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International 
Workshop. Neurology 1996a; 47: 1-9. 
 
  
33 
13. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, 
Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. Validity and reliability of 
the preliminary NINDS neuropathological criteria for progressive supranuclear palsy and 
related disorders. J Neuropath Exp Neurol 1996b; 55 (1): 97-
105.DOI:10.1097/00005072-196601000-00010 
 
14. Gilman S, Wenning GJK, Low PA, Brooks DJ, Mattias CJ, Trojanowski JQ, Wood NW, 
Colosima C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poese W, Quinn N, 
Revesz T, Robertson D, Sandroni T, Seppi K, Vidailhet M. Second consensus statement on the 
diagnosis of multiple system atrophy. Neurology 2008; 71 (9): 670-676. 
DOI:10.1212/01.wnl.0000324625.00404.15 
 
15. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos 
PL, Lippa CF, Mirra SS, Tabaton M, Vonsattel JP, Wakabayashi K, Litvan I. Office of rare 
diseases neuropathologic criteria for corticobasal degeneration. J Neuropath Exp Neurol 2002; 61 
(11): 935-946. DOI:10.1093/jnen/61.11.935 
 
16. Sagar H. Parkinson's disease. Optima Health Guides. Macdonald & Co., London, 
1991. 
 
17. Walton J. Brain's Diseases of the Nervous System. pp 322-336, Oxford University 
Press, Oxford, 1985. 
 
18. Wu T, Wang J, Wang CD, Hallett M, Zang YF, Wu XL, Chan P. Basal ganglia 
circuits changes in Parkinson’s disease. Neurosci Lett 2012; 524 (1): 55-59. 
DOI:10.1016/j.neulet.2012.07.012 
 
19. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. 
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s 
disease and dementia with Lewy bodies. Neurosci Lett 1998; 251 (3): 205-208. 
 
  
34 
20. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alpha-synuclein 
correlates with striatal dopamine deficit. Move Disord 2008; 23 (11): 1608-1612. 
DOI:10.1002/mds.22207 
 
21. Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: A 
comparative clinicopathological study. Ann Neurol 1994; 35 (1): 81-88. 
DOI:10.1002/ana.410350113 
 
22. Galasko D, Katzman R, Salmon DP, Hansen I. Clinical and neuropathological 
findings in Lewy body dementias. Brain Cog 1996; 31(2): 166-175. 
DOI:10.1006/brcg.1996.0040 
 
23. Cummings JL. Dementia with Lewy bodies: Molecular pathogenesis and implications 
for classification. J Geriatr Psychol Neurol 2004; 17 (3): 112-119. 
DOI:10.1177/0891988704267473 
 
24. Mann DMA, Snowden JS. The topographic distribution of brain atrophy in cortical 
Lewy body Disease: comparison with Alzheimer’s disease. Acta Neuropathol 1995; 89 
(2): 178-183. 
 
25. Robles A, Cacabelos P. Dementia with Lewy Bodies: New data for the understanding 
of neuroimaging. Rev Neurol 1999; 29 (11): 993-998. 
 
26. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson’s disease with 
dementia from dementia with Lewy bodies? Acta Neuropathol  2006; 112 (3): 253-260. 
DOI:10.1007/s00401-006-0088-2 
 
27. Perneczky R, Haussermann P, Diehl-Schmid J, Boecker H, Forstl H, Drzezga A, Kurz 
A. Metabolic correlates of brain reserve power in dementia with Lewy bodies: An FDG 
PET study. Dem Geriatr Cog Disord 2007; 23 (6): 416-422. DOI:10.1159/000101956 
 
  
35 
28. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease 
relate to Lewy bodies in the temporal lobe. Brain 2002; 125 (2): 391-403. 
DOI:10.1093/brain/awf033 
 
29. Steele JC, Richardson JC, Olszewski T. Progressive supranuclear palsy. Arch Neurol 
1964; 10: 333-359. 
 
30. Papapetropoulos S, Gonzalez J, Mash DC. Natural history of progressive 
supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur 
Neurol 2005; 54 (1): 1-9. DOI:10.1159/000086754 
 
31. Gomez-Haro C, Espert-Tortajada R, Gadea-Domenech M, Navarro-Humanes JF. 
Progressive supranuclear palsy: Neurological, neuropathological and neuropsychological 
aspects. Revis Neurol 1999; 29 (10): 936-956. 
 
32. Saini J, Bagepally BS, Sandhya M, Pasha SA, Yadav R, Thennarasu K, Pal PK. 
Subcortical structures in progressive supranuclear palsy: vertex-based analysis. Eur J 
Neurol 2013; 20 (3): 493-501. DOI:10.1111/j.1468-1331.2012.03884.x 
 
33. Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JGL. Regional brain 
atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000; 47 
(6): 718-728. DOI:10.1002/1531-8249(200006)47:6<718::AID.ANA4>3.0.CO;2-J 
 
34. Armstrong RA, Lantos PL, Cairns NJ. Progressive supranuclear palsy (PSP): a 
quantitative study of the pathological changes in cortical and subcortical areas of eight 
cases. J Neural Transm 2007; 114 (12): 1569-1577. DOI:10.1007/s00702-007-0796-3 
 
 
35. Conrad C, Andreadis A, Trojanwski JQ, Dickson DW, Kang D, Chen XH, 
Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. Genetic 
  
36 
evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 
41 (2): 277-281.DOI:10.1002/ana.410410222 
 
36. Probst-Cousin S, Kayser C, Heuss D, Neundorfer B. Thirty years of multiple system 
atrophy concept: Review and survey of multiple system atrophy. Fortschritte Neurol 
Psych 2000; 68 (1): 25-36. DOI:10.1055/s-2000-11790 
 
37. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system 
atrophy: a review of 203 pathologically proven cases. Move Disord 1997; 12 (2): 133-
147. DOI:10.1002/mds.870120203 
 
38. Horimoto Y, Aiba I, Yasuda T, Ohkawa Y, Katayama T, Yokokawa Y, Goto A, Ito 
Y. Cerebral atrophy in multiple system atrophy by MRI. J Neurol Sci 2000; 173 (2): 109-
112. DOI:10.1016/S0022-510X(99)00308-1 
 
39. Konagaya M, Sakai M, Matsuoka Y. Konagaya Y, Hashizume Y. Multiple system 
atrophy with remarkable frontal lobe atrophy. Acta Neuropathol 1999; 97 (4): 423-428. 
 
40. Tsuchiya K, Watabiki S, Sano M, Iobe H, Shiotsu H, Taki K, Hashimoto K. 
Distribution of cerebellar cortical lesions in multiple system atrophy: a topographic 
neuropathological study of three autopsy cases in Japan. J Neurol Sci 1998; 155 (4): 80-
85. DOI:10.1016/S0022-510X(97)00279-7 
 
41. Lantos PL. Cellular pathology of multiple system atrophy: a review. J Neurol 
Neurosurg Psy 1994; 57 (2): 129-13. DOI:10.1136/jnnp.57.2.129 
 
42. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients 
with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy, 
and Shy-Drager syndrome). J Neurol Sci 1989; 94 (1-3): 79-100. DOI:10.1016/0022-
510X(89)90219-0 
 
  
37 
43. Dickson DW, Liu WL, Liu WK, Yen SH. Multiple system atrophy: a sporadic 
synucleinopathy. Brain Pathol 1999; 9 (4): 721-732. 
 
44. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration:  a 
clinical study of 36 cases. Brain 1994; 117 (5): 1183-1196. 
DOI:10.1093/brain/117.5.1183 
 
45. Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal 
degeneration: Neuropathological and clinical heterogeneity. Neurology 1997; 48 (4): 
959-969. 
 
46. Ueno E. Clinical features of corticobasal degeneration. Neuropathology 1996; 16 (4): 
253-256. DOI:10.1111/j.1440-1789.1996.tb00190.x 
 
47. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Park Dis Rel 
Disord 2007; 13 (3): S336 – S340. DOI:10.1016/S1353-8020(08)70027-0 
 
48. Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, 
Jellinger K, Chandhuri KR, D’Olhaberriague L, Pearce RKB. Natural history and 
survival of 14 patients with corticobasal degeneration confirmed at postmortem 
examination. J Neurol, Neurosurg Psych 1998; 64 (2): 184-189. 
DOI:10.1136/jnnp.64.2.184 
 
49. Tsuchiya K, Ikeda K, Uchihara T, Oda T, Shimada H. Distribution of cerebral cortical 
lesions in corticobasal degeneration: a clinicopathological study of five autopsy cases in 
Japan. Acta Neuropathol 1997; 94 (5): 416-424. DOI:10.1007/s004010050728 
 
50. Ikeda K. Basic pathology of corticobasal degeneration. Neuropathology 1997; 17 (2): 
127-133. DOI:10.1111/j.1440-1789.tb00026x 
 
  
38 
51. Markus HS, Lees AJ, Lennox G, Marsden CD, Costa DC. Patterns of regional 
cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT: 
Comparison with Parkinson's disease and normal controls. Movement Disorders 1995; 10 
(2): 179-187. DOI:10.1002/mds.870100208 
 
52. Kawasaki K, Iwanaga K, Wakabayashi K, Yamada M, Nagai H, Idezuka J, Homna Y, 
Ikuta F. Corticobasal degeneration with neither argyrophilic inclusions nor tau 
abnormalities: a new subgroup. Acta Neuropathol 1996;  91 (2): 140-144. 
 
53. Rippon GA, Staugaitis SM, Chin SS, Goldman JE, Marder K. Corticobasal syndrome 
with novel argyrophilic glial inclusions. Movement Disorders 2005; 20 (5): 598-602. 
DOI:10.1002/mds.20396 
 
54. Mori H, Oda M. Ballooned neurons in corticobasal degeneration and progressive 
supranuclear palsy. Neuropathology 1997; 7 (3): 248-252. DOI:10.1111/j.1440-
1789.1997.tb00047.x 
 
55. Komori T, Arai N, Oda M, Nakayama H, Murayama S, Amano N, Shibata N, 
Kobayashi M, Sasaki S, Yagishita S. Morphologic differences in neuropil threads in 
Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy: a 
morphometric study. Neurosci Lett 1997; 233 (2-3): 89-92. DOI:10.1016/S0304-
3940(97)00635-6 
 
56. Matsumoto S, Udaka F, Kameyama M, Kusaka H, Ito H, Imai T. Subcortical 
neurofibrillary tangles, neuropil threads and argentophilic glial inclusions in corticobasal 
degeneration. Clin Neuropathol 1996; 15 (4): 209-214. 
 
57. Dickson DW, Feany MB, Yen SH, Mattiace LA, Davies P. Cytoskeletal pathology in 
non-Alzheimer degenerative dementia: new lesions in diffuse Lewy body disease, Pick's 
disease and corticobasal degeneration. J Neural Transm 1996; 47: 31-46. 
 
  
39 
58. Armstrong RA, Kergoat H. Oculo-visual changes and clinical considerations 
affecting older patients with dementia. Ophthal Physiol Opt 2015; 35 (4): 352-376. 
DOI:10.10.1111/opo.12220 
 
59. Metzler-Baddeley C, Baddeley RJ, Lovell PG, Laffan A, Jones RW. Visual 
impairment in dementia with Lewy bodies and posterior cortical atrophy. 
Neuropsychology 2010; 24 (1): 35-48. DOI:10.137/a0016834 
 
60. Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson's disease. 
J Pediat Ophth Strab 1996; 33 (3): 144-147. 
 
61. Jones RD & Donaldson IM. Fractionation of visuo-perceptual dysfunction in 
Parkinson's disease. J Neurol Sci 1995; 131 (1): 43-50. DOI:10.1016/0022-
510X(95)00043-2 
 
62. Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual activity 
in Parkinson's disease. Move Disord 1992; 7 (3): 232-238. DOI:10.1002/mds.870070308 
 
63. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M. 
Impaired visual acuity as a risk factor for visual hallucinations in Parkinsons’s disease. J 
Geriatr Psych Neurol 2006; 19 (1): 36-40. DOI:10.1177/0891988705284739 
 
64. Rajagopal R, Bateman R, Van Stavern GP. Visual involvement in corticobasal 
syndrome. J Neuro-ophthalmol 2012; 32 (4): 338-340. 
DOI:10.1097/WNO.Ob013e3182305162 
 
65. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and 
contrast sensitivity in Parkinson's disease. Neurology 1992; 42 (4): 887-890. 
 
  
40 
66. Buttner T, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru U, Przuntek H. 
Disturbance of color perception in Parkinson's disease. J Neural Transm 1993 (1); 6: 11-
15. DOI:10.1007/BF02252618 
 
67. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and 
chromatic processing deficits in Parkinson’s disease. Arch Neurol 2002; 59 (8): 1249-
1252. DOI:10.001/archneur.59.8.1249 
 
68. Vesela O, Ruzicka E, Jech R, Roth J, Stepankova K, Mecir P, Solano Z, Preclikova E. 
Color discrimination is not a reliable early marker of Parkinson’s disease. J Neurol 2001; 
248 (11): 975-978. DOI:10.1007/s004150170051 
 
69. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and 
color vision identify impending neurodegeneration in rapid eye movement sleep disorder. 
Ann Neurol 2011; 69 (5): 811-818. DOI:10.1002/ana.22282 
 
70. Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growden JH, Banks KS. Visual 
dysfunction in Alzheimer's disease: relation to normal ageing. Ann Neurol 1991; 29 (1): 
41-52. DOI:10.1002/ana410290110 
 
71. Kiyosawa M, Bosley TM, Chawluk J, Jamieson D, Schatz NJ, Savino PJ, Sergott RC, 
Reivich M, Alavi A. Alzheimer's disease with prominent visual symptoms; clinical and 
metabolic evaluation. Ophthalmology 1989; 96 (7): 1077-1085. 
 
72. Sun L, Zhang H, Gu ZQ, Cao M, Li DW, Chan P. Stereopsis impairment is associated 
with decreased color perception and worse motor performance in Parkinson’s disease. 
Eur J Med Res 2014; Article number 19.  
 
73. Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JB. Effect of levodopa 
treatment on contrast sensitivity in Parkinson's disease. Ann Neurol 1987 (3); 22: 365-
369. DOI:10.1002/ana.41022031(3) 
  
41 
 
74. Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in 
Parkinson's disease. Arch Neurol 1993; 50 (7), 721-724. 
 
75. Rodnitzky RL. Visual dysfunction in Parkinson’s disease. Clin Neurosci 1998 (2); 5: 
102-106. 
 
76. Buttner T, Muller T, Kuhn W. Effects of apomorphine on visual functions in 
Parkinson’s disease. J Neural Transm 2000; 107 (1): 87-94. 
DOI:10.1007/s007020050007 
 
77. Rascol O, Sabatini U, Fabre N, Senard JM, Simonett-Amoreau M, Montastruc JL 
Clanet M, Rascol A. Abnormal vestibulo-ocular cancellation in multiple system atrophy 
and progressive supranuclear palsy but not in Parkinson’s disease. Movement Disorders 
1995; 10 (2): 163-170. DOI:10.1002/mds.870100206 
 
78. Ture S, Inci I, Gedizlioglu M. Abnormalities of contrast sensitivity, visual fields and 
visual evoked potentials in Parkinson’s disease and effect of dopaminergic treatment. J 
Neurol 2007; 254 (3): 93-93. 
 
79. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with 
neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and 
Parkinson’s disease. Am J Ophthalmol 2002; 133 (1): 135-137. DOI:10.1016/S0002-
9394(01)01196-5 
 
80. Biousse V, Newman NJ, Carroll C, Mewes K, Vitek JL, Bakay RAE, Baron MS, 
DeLong MR.  Visual fields in patients with posterior GPi pallidotomy. Neurology 1998; 
50 (1): 258-265. DOI:10.1212/WNL.50.1.258 
 
81. Bashir K, Elbe RJ, Ghabrial M, Struble RG. Hemianopsia in dementia with Lewy 
bodies. Arch Neurol 1998; 55(8): 1132-1135. DOI:10.1001/archneur.55.8.1132 
  
42 
 
82. Lobotesis K, Fenwick JD, Phipps A, Tyman A, Swann A, Ballard C, McKeith IG, 
O’Brien JT. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not 
Alzheimer’s disease. Neurology 2001; 56 (5): 643-649. 
 
83. Barnes CS, Yan J, Wilmot GR. A negative electroretinogram (ERG) in a case of 
probable multiple system atrophy (MSA). Doc Ophthalmol 2009; 118 (3): 247-256. 
DOI:10.1007/s10633-0088-9156-3 
 
84. Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. 
J Neurol Transm (Supp) 1994; 42: 33-41. 
 
85. Valls-Sole J, Valldeoriola F, Tolosa E, Marti MJ. Distinctive abnormalities of facial 
reflexes in patients with progressive supranuclear palsy. Brain 1997; 120 (10): 1877-
1883. DOI:10.1093/brain/120.10.1877 
 
86. Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of 
eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med 
Rehab 1997; 78 (5): 525-529. DOI:10.1016/S0003-9993(97)90169-6 
 
87. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman, NJ. 
Ophthalmologic features of Parkinson’s disease. Neurology 2004; 62 (2): 177-180. 
 
88. Peshori KR, Schicatano EJ, Gopalaswamy R, Sahay E, Evinger C. Aging of the 
trigeminal blink system. Exp Brain Res 2001; 136 (3): 351-363. 
DOI:10.1007/s002210000585 
 
89. Bonanni L, Anzelloti F, Varanese S, Thomas A, Manzoli L, Onofrj M. Delayed blink 
reflex in dementia with Lewy bodies. J Neurol Neurosurg Psychiatr 2007; 78 (10): 1137-
1139. DOI: 10.1136/jnnp.2006.113746 
 
  
43 
90. Anzellotti F, Bonanni L, Iorio E, Di Baldassarre F, D’Andreagiovanni A, Monaco D, 
Thomas A, Onofrj M. Delayed blink reflex in dementia with Lewy bodies is sensitive to 
cholinergic stimulation. Clin Neuropharmacol 2008; 31 (4): 231-237. 
DOI:10.1097/WNF.OBO13E31815E5D7F 
 
91. Kagohashi M, Okuma Y, Fujishima K, Kitada Y, Mizuno Y. Blepharospasm 
associated with multiple system atrophy: a case report and review of the literature. Parkin 
Rel Disord 2004; 10 (3): 169-171. DOI:10.1016/j.parkreldis.2003.12.002 
 
92. Sepe-Monti M, Giubilei F, Marchione F, Colosimo C. Apraxia of eyelid opening in a 
case of atypical corticobasal degeneration. J Neural Transm 2003; 110 (10): 1145-1148. 
DOI:10.1007/S00702-003-0032-8 
 
93. Tolosa E, Compta Y. Early and prominent blepharospasm in untreated patients with 
Parkinsonism should raise suspicion of progressive supranuclear palsy, multiple system 
atrophy, or corticobasal degeneration. J Neurol 2005; 253: 7-13. 
 
94. Leon-Sarmiento FE, Bayona-Prieto J, Gomez J. Neurophysiology of blepharospasm 
and multiple system atrophy: clues to pathophysiology. Parkinsonism Relat D 2005; 11 
(3): 199-201. DOI:10.1016/jparkreldis.2004.07.011 
 
95. Rana AQ, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and 
apraxia of eye opening in patients with Parkinsonism, cervical dystonia, and essential 
tremor. Eur Neurol 2012; 68 (5): 318-321. DOI:10.1159/000341621 
 
96. Scinto LFM, Daffner KR, Dressler D, Ransil BI, Rentz D, Wientraub S, Mesulam, M, 
Potter H. Potential non-invasive neurobiological test for Alzheimer's disease. Science 
1994; 266 (5187): 1051-1054. DOI:10.1126/science.7973660 
 
97. Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects 
on pupil size and papillary light reflexes in Alzheimer’s and Parkinson’s disease. Int J 
Psychophysiol 2003; 47(2): 95-115. DOI:10.1016/S0167-8760(02)00122-8 
  
44 
 
98. Litvan I, FitzGibbon EJ. Can tropicamide eye drop response differentiate patients 
with progressive supranuclear palsy and Alzheimer’s disease from healthy control 
subjects? Neurology 1996; 47 (5): 1324-1326. 
 
99. Hanyu H, Hirao K, Shimizu S, Kanetaka H, Sakurai H, Iwamoto T. Phenylephrine 
and pilocarpine eye drop test for dementia with Lewy bodies and Alzheimer’s disease. 
Neurosci Lett 2007; 414(2): 174-177. DOI:10.1016/j.neulet.2006.12.015 
 
100. Schmidt C, Herling B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schols L, 
Antoni S, Ferger D, Reichmann H, Wilhelm H, Berg D, Ziemssen T. Pupil diameter in 
darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal 
syndromes. Move Disord 2007: 22 (14): 2123-2126. DOI:10.1002/mds.21721 
 
101. Kuroda M, Fukura H, Saruki N, Yoshikawa D, Morita T, Goto F. Vecuronium dose 
requirement and pupillary response in a patient with olivopontocerebellar atrophy 
(OPCA). Can J of Anaesthesia 1998; 45 (10): 979-984. DOI:10.1136/jnnp.66.1.48 
 
102. Smith SA, Smith SE. Bilateral Horner’s syndrome: detection and occurrence. J 
Neurol Neurosurg Psychiatr 1999; 66 (1): 48-51. 
 
103. Rascol O, Sabatini U, Simonett-Amoreau M, Montrastruc JL, Rascol A, Clanet M 
Square-wave jerks in Parkinsonism syndromes. J Neurol Neurosurg Psy 1991; 54 (7): 
599-602. DOI:10.1136/jnnp.54.7.599 
 
104. Friedman DI, Jankovic J, McCrary JA. Neuro-ophthalmic findings in progressive 
supranuclear palsy. J Clin Neuro-ophthalmol 1992; 12 (2): 104-109. 
 
105. Koop G, Graerf M. Steele-Richardson-Olszewski Syndrome: A report on two cases. 
Klin Monats Augenheil 2007; 224 (10): 799-803. DOI:10.1055/s-2007-963605 
 
  
45 
106. Lepore E. Parkinson’s disease and diplopia. Neuro-opthalmol 2006; 30 (2-3): 37-40. 
DOI:10.1080/01658100600742838 
 
107. Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson's disease. 
Arch Neurol-Chicago 1979; 36 (6): 360-364. 
 
108. Michell AW, Xu Z, Lewis SJG, Foltynie T, Williams-Gray CH, Robbins TW, 
Carpenter RHS, Barker RA Saccadic latency distribution in Parkinson’s disease and the 
effects of L-dopa. Exp Brain Res 2006; 174 (1): 7-18. DOI:10.007/s00221-006-0412-z 
 
109. Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in 
Parkinson's disease: manual keypresses and saccadic eye movements to regular stimulus 
events. J Neurol Neurosurg Psych 1989; 52 (9): 1033-1042. DOI:10.1136/jnnp.52.9.1033 
 
110. Winograd-Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB. 
Self-paced saccades and saccades to oddball targets in Parkinson’s disease. Brain 
Research 2006 Aug; 1106, 134-141. DOI:10.1016/j.brainres.2006.05.103 
 
111. Lekwuwa GU, Barnes GR, Collins CJS, Limousin P. Progressive bradykinesia and 
hypokinesia of ocular pursuit in Parkinsons’s disease. J Neurol Neurosurg Psych 1999, 66 
(6), 746-753.DOI:10.1136/jnnp.66.6.746 
 
112. Corin MS, Elizan TS, Bender MB. Oculomotor function in patients with Parkinson's 
disease. J Neurol Sci 1971; 15: 251-265. 
 
113. Mosimann UP, Muri RM, Burn DJ, Felblinger J, O’Brien JT, McKeith IG. Saccadic 
eye movement changes in Parkinson’s disease dementia and dementia with Lewy bodies. 
Brain 2005; 128 (6): 1267-1276. DOI:10.1093/brain/awh484 
 
  
46 
114. Debruin VM. Lees AJ,Daniel SE. Diffuse Lewy body disease presenting with 
supranuclear gaze palsy, Parkinsonism and dementia: a case report. Movement Disord 
1992; 7 (4): 355-358. DOI:10.1002/mds.870070410 
 
115. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body 
disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psych 1991; 54 
(2): 159-161. DOI:10.1136/jnnp.542.159 
 
116. Brett FM, Henson C, Staunton H. Familial diffuse Lewy body disease, eye 
movements, eye movement abnormalities and distribution of pathology. Arch Neurol 
2002; 59 (3): 464-467. DOI:10.1001/archneur.59.3.464 
 
117. Pinkhardt EH, Jurgens R, Becker W, Valdarno F, Ludolph AC, Kassubek J. 
Differential diagnostic value of eye movement recording in PSP-Parkinsonism, 
Richardson’s syndrome, and idiopathic Parkinson’s disease. J Neurol 2008; 155 (12): 
1916-1925. DOI:10.1007/S00415-009-0027-y 
 
118. Kim C, Lee HW, Park MY. Exodeviated ophthalmoplegia in a patient with 
progressive supranuclear palsy. J Kor Med Sci 2009; 24 (5): 982-984. 
DOI:10.13346/jkms.2009.24.5.982 
 
119. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-
Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and 
progressive supranuclear palsy. Neurology 2000; 54 (5): 1029-1032. 
 
120. Bhidayasiri R, Riley DE, Somers JT, Lerner AJ, Buttner-Ennever JA, Leigh RJ. 
Pathophysiology of slow vertical saccades in progressive supranuclear palsy. Neurology 
2001; 57 (11): 2070-2077. 
 
  
47 
121. Rottach KG, Riley DE, DiScenna AO, Zivotofsky AZ, Leigh RJ. Dynamic 
properties of horizontal and vertical eye movements in Parkinsonism syndromes. Ann 
Neurol 1996; 39 (3): 368-377. DOI:10.1002/ana.410390314 
 
122. Das VE, Leigh RJ. Visual-vestibular interaction in progressive supranuclear palsy. 
Vision Res 2000; 40 (15): 2077-2081. DOI:10.1016/S0042-6989(00)00046-8 
 
123. Malessa S, Gaymard B, Rivaud S, Cervera P, Hirsch H, Verny M, Duyckaerts C, 
Agid Y, Pierrot-Deseilligny C. Role of pontine nuclei damage in smooth-pursuit 
impairment of progressive supranuclear palsy: a clinico-pathological study. Neurology 
1994; 44 (4): 716-721. 
 
124. Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of 
optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psych 
2004; 75 (10): 1386-1394. DOI:10.1136/jnnp.2003.027367 
 
125. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with 
pathologically proven multiple system atrophy: A meta analysis. Neurology 1997; 48 (2): 
384-393. 
 
126. Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor 
function in multiple system atrophy: clinical and laboratory features in 30 patients. Move 
Disord 2008; 23 (7): 977-984. DOI:10.1002/mds.21999 
 
127. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in 
cortical-basal ganglionic degeneration: Differentiation from Alzheimer’s disease. 
Neurology 1996; 46 (3): 720-726. 
 
128. Pierrot-Desilligny C, Rivaud-Pechoux S. Contribution of oculomotor exploitation 
for the etiological diagnosis of Parkinsonism syndromes. Rev Neurologique. 2003; 159 
(5): S75-S81. 
  
48 
 
129. Vidailhet M, Rivaud S, Guiderkhouja N, Pillon B, Bonnet AM, Gaymard B, Agid Y, 
Pierrot-Deseilligny C. Eye-movements in Parkinsonism syndromes. Ann Neurol 1994; 35 
(4): 420-426. DOI:10.1002/ana.410350408 
 
130. Altiparmak UE, Eggenberger E, Coleman A, Condon K. The ratio of square wave 
jerk rates to blink rate distinguishes progressive supranuclear palsy from Parkinson’s 
disease. J Neuro-ophthalmol 2006; 26 (4): 257-259. 
DOI:10.1097/01.wno.0000249326.65227.2e 
 
131. Pugnetti L, Baglio F, Farina E, Alberoni M, Calbrese E, Gambini A, DeBella E, 
Garegnani M, Deleonardis L, Neuini R. EEG evidence of posterior cortical disconnection 
in Parkinson’s disease and related dementias. Int J Neurosci 2010; 120 (2): 88-98. 
DOI:10.3109/0020745090343646 
 
132. Tashiro K, Ogata K, Goto Y, Taniwaki T, Okayama A, Kira J, Tobimatsu S. EEG 
findings in early-stage corticobasal degeneration and progressive supranuclear palsy: A 
retrospective study and literature review. Clin Neurophys 2006; 117 (10): 2236-2242. 
DOI:10.1016/jclinph.2006.06.710 
 
133. Devos D, Tir M, Maurage CA, Waucquier N, Defebvre L, Defoort-Dhellmmes S, 
Destee A. ERG and anatomical abnormalities suggesting retinopathy in dementia with 
Lewy bodies. Neurology 2005; 65 (7): 1107-1110. 
DOI:10.1212/01.wnl.0000178896.44905.33 
 
134. Langheinrich T, van Elst LT, Lagreze WA, Bach M Lucking CH, Greenlee MW. 
Visual contrast response functions in Parkinson’s disease: evidence from 
electroretinogram, visually evoked potentials and psychophysics. Clin Neurophysiol 
2000; 111 (1): 66-74. DOI:10.1016/S1388-2457(99)00223.0 
 
  
49 
135. Sartucci F, Orlandi G, Bonuccelli U, Borghetti D, Murri L, Orsini C, Domenici L, 
Porciatti V. Chromatic pattern-reversal electroretinogram (ChPERG) are spared in 
multiple system atrophy compared with Parkinson’s disease. Neurol Sci 2006; 26 (6): 
395-401. DOI:10.1007/s10072-006-0522-1 
 
136. Buttner T, Kuhn W, Muller T, Heinze T, Puhl C, Przuntek H. Chromatic and 
achromatic visual evoked potentials in Parkinson’s disease. Electroen Clin Neurol 1996; 
100 (5): 443-447. 
 
137. Masanaka T, Hisao T, Keita K, Yasunobu K, Hiroo Y, Bungo O. Multi-modal 
evoked potentials in corticobasal degeneration, progressive supranuclear palsy, and 
Alzheimer’s disease. In: Unveiling the mystery of the brain: Neurophys Inv Brain Func: 
Int Cong Ser 2005; 1278: 145-148. DOI:10.1016/j.ics.2004.11.069 
 
138. Delalande I, Hache JC, Forzy G, Bughin M, Benhadjali J, Destee A. Do visual 
evoked potentials and spatial-temporal contrast sensitivity help to distinguish idiopathic 
Parkinson’s disease and multiple system atrophy. Move Disord 1998; 13 (5): 446-452. 
DOI:10.1002/mds.870130312 
 
139. Pierrot-Deseilligny C, Turell E, Penet C, Lebrigand D, Pillon B, Chain F, Agid Y 
Increased wave P300 latency in progressive supranuclear palsy. J Neurol Neurosurg 
Psych 1989; 52 (5): 656-658. DOI:10.1136/jnnp.52.5.656 
 
140. Johnson R, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory 
processing leads to degraded cognition. Neurology 1991; 41 (8): 1257-1262. 
 
141. Koga Y, Nagata K, Hirata K. Hypothesis on the P300 generators based on visual 
P300 results in neurological disorders. Brain Topog Tod: Int Cong Series 1997; 1147: 
354-357. 
 
  
50 
142. Wang LH Kuroiwa Y, Kamitani T, Li M, Takahashi T, Suzuki Y, Shimamura M, 
Hasegawa O. Visual event-related potentials in progressive supranuclear palsy, 
corticobasal degeneration, striatonigral degeneration and Parkinsons’s disease. J Neurol 
2000; 247 (5): 356-363. DOI:10.1007/s004150050602 
 
143. Kamitani T, Kuroiwa T, Wang LH, Li M, Suzuki Y, Takahashi T, Ikegami T, 
Matsubara S. Visual event-related potential changes in two subtypes of multiple system 
atrophy, MSA-C and MSA-P. J Neurol 2002; 249 (8): 975-982. DOI:10.1007/S00415-
002-0764-7 
 
144. Kamitani T, Kuroiwa Y. Visual event-related potential changes in multiple system 
atrophy: delayed N2 latency in selective attention to a color task. Park Dis Rel Disord 
2009; 15 (1): 36-40. DOI:10.1016/jparkreldis.2008.02.009 
 
145. Mori E, Shimomura T, Fujimori M, Horono N, Imamura T, Hashimoto M, 
Tanimukai S, Kaui H, Hanihara T. Visuoperceptual impairment in dementia with Lewy 
bodies. Arch Neurol 2000; 57 (4): 489-493. DOI:10.001/archneur.57.4.489 
 
146. Metzler-Baddeley C, Baddeley RJ, Lovell PG, Laffan A, Jones RW. Visual 
impairment in dementia with Lewy bodies and posterior cortical atrophy. Neuropsych 
2010; 24 (1): 35-48. DOI:10.1037/a0016834 
 
147. Mondon K, Gochard A, Margue A, Armand A, Beauchamp D, Pruncer C, Jacobi D, 
de Toffol B, Autret A, Camus V, Hommet C. Visual recognition memory differentiates 
dementia with Lewy bodies and Parkinson’s disease dementia. J Neurol Neurosurg Psych 
2007; 78 (7): 738-741. DOI:10.1136/jnnp.104257 
 
148. Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brwon 
MC. Visuospatial impairments in Parkinson's disease.  Neurology 1991; 41 (3): 365-369. 
 
  
51 
149. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in 
Parkinsons’s disease. Vision Res 2005; 45 (10): 1285-1296. 
DOI:10.1016/j.visres.2004.11.006 
 
150. Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is 
more impaired in dementia with Lewy bodies than in Alzheimer’s disease. J Neurol 
Neurosurg Psych 2001; 70 (4): 483-488. DOI:10.1136/jnnp.70.4.483 
 
151. Trick GL, Kaskie B, Steinman SB. Visual impairment in Parkinson's disease: 
Deficits in orientation and motion discrimination. Optometry Vis Sci 1994; 71 (4): 242-
245. DOI:10.1097/00006324-199404000-00002 
 
152. Lang PJ. A bio-informational theory of emotional imagery. Psychophysiology 1979; 
16 (6): 495-512. DOI:10.1111/j.1469-8986.1979.tb.01511.x 
 
153. Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Woitalla D, Buttner T, Kuhn 
W, Przuntek H. Facial expression recognition in people with medicated and unmedicated 
Parkinson’s disease. Neuropsychology 2003; 41 (8): 1047-1057. DOI:10.1016/S0028-
3932(02)00295-6 
 
154. Jacobs DH, Shuren J, Bowers D, Heilman KM. Emotional facial imagery, 
perception and expression in Parkinson's disease. Neurology 1995; 45 (9): 1696-1702. 
 
155. Podoll K, Schwarz M, Noth J. Language problems in progressive supranuclear 
palsy. Brain 1991; 114 (3): 1457-1472. DOI:10.1093/brain/114.3.1457 
 
156. Sachin S, Shukla G, Goyal V, Singh S, Aggarwal V, Guresh-Kumar, Behari M. 
Clinical speech impairment in Parkinson’s disease, progressive supranuclear palsy, and 
multiple system atrophy. Neurology India 2008; 56 (2): 122-126. 
 
  
52 
157. Jellinger KA, Grazer A, Petrovic K, Ropele S, Alpi G, Kapeller P, Strobel T, 
Schmidt R. Four-repeat tauopathy clinically presenting as posterior cortical atrophy: 
atypical corticobasal degeneration? Acta Neuropathol 2011; 121 (2): 267-277. 
DOI:10.1007/s00401-010-0712-z 
 
158. Bak TH, Caine D, Nearn VC, Hodges JR. Visuospatial functions in atypical 
Parkinsonism syndromes. J Neurol Neurosur PS 2006: 77 (4): 454-456. 
DOI:10.1136/jnnp.2005.068239 
 
159. Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in 
corticobasal degeneration. Neurology 2003: 61 (4): 493-499. 
 
160. Tang-Wai DF, Josephs KA, Boeve BF, Dickson DW, Parisi JE, Petersen RC. 
Pathologically confirmed corticobasal degeneration presenting with visuospatial 
dysfunction. Neurology 2003; 61 (8): 1134-1135. 
DOI:10.1212/01.WNL.0000086814.35352.B3 
 
161. Chapman FM, Dickinson J, McKeith I, Ballard C. Association among visual 
associations, visual acuity, and specific eye pathologies in Alzheimer’s disease: 
Treatment implications. Am J Psych  1999; 156 (12): 1983-1985. 
 
162. Archibald NK, Clarke MP, Mosimann UP, Burn, D.J. Visual symptoms in 
Parkinson’s disease and Parkinson’s disease dementia. Movement Disord 2011; 26 (13): 
2387-2395. DOI:10.1002/mds.23891 
 
163. Ebersbach G. Hallucinations and psychosis in Parkinson’s disease: consequences for 
diagnosis and management. Nervenheilkundt 2008; 27: 709. 
 
164. Hely MA, Reid WG, Halliday GM, McRitchie DA, Leicester J, Joffe R, Brooks W, 
Broe GA, Morris JGL. Diffuse Lewy body disease: clinical features in nine cases without 
  
53 
coexistant Alzheimer’s disease. J Neurol Neurosurg Psych 1996; 60 (5): 531-538. 
DOI:10.1136/jnnp.60.5.531 
 
165. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in 
Parkinsons’s disease as disturbed external/internal perceptions: Focused review and a 
new integrative model. Movement Disord 2005; 20 (2): 130-140. 
DOI:10.1002/mds.20308 
 
166. Oertel WH, Depboylu C, Krenzer M, Vadasz D, Ries V, Sixel-Doring F, Mayer G 
REM sleep behavior disorder as a prodromal stage of alpha-synucleinopathies: 
Symptoms, epidemiology, pathophysiology, diagnosis and therapy. Nervenarzt 2014; 85 
(1), 19-25. DOI:10.1007/s00115-013-3891-8 
 
167. Turner RS. Idiopathic rapid eye movement sleep behavior disorder is a harbinger of 
dementia with Lewy bodies. J Geriatr Psych Neur 2002; 15 (4): 195-199. 
 
168. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep 
behavior disorder in progressive supranuclear palsy and corticobasal degeneration: A 
prospective study. Parkinsonism Relat D 2009, 15 (1): 59-61. 
DOI:10.1016/j.parkeldis.2008.01.011 
 
169. Postuma RB, Gagnon JF, Pelletier A,  Montplaisir J. Prodromal autonomic 
symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Movement 
Disord 2013; 28 (5): 597-604. DOI:10.1002/mds.25445 
 
170. Bares M, Brazdil M, Kanovsky P, Jurak P, Daniel P, Kukleta M, Rektor I. The effect 
of apomorphine administration on smooth pursuit ocular movements in early Parkinson’s 
disease. Parkinson Rel Disord 2003; 9 (3), 139-144. DOI:10.1016/S1353-8020(02)00015-
9 
 
  
54 
171. Sato E, Onitsuka T, Ninomiya H, Nakamura I,  Kanba S. Prism adaptation and 
perceptual skill learning deficits in early-stage Parkinson’s disease. Neuropsychobiology 
2014; 70 (3): 165-172. DOI:10.1159/000365485 
 
172. Goldman JG, Postuma R. Premotor and non-motor features of Parkinson’s disease. 
Curr Opin Neurol 2014; 27(4): 434-441. DOI:10.1097?WCO.0000000000000112 
 
173. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to 
differentiate Parkinson’s disease from atypical Parkinsonism. J Neurol Neurosurg Psych 
2008; 79 (6): 652-655. DOI:10.1136/jnnp.2007.124677 
 
174. Averbuch-Heller L, Paulson GW, Daroff RB, Leigh RJ. Whipple’s disease 
mimicking progressive supranuclear palsy, the diagnostic value of eye movement 
recording. J Neurol Neurosurg Psych 1999; 66 (4): 532-535. DOI:10.1136/jnnp.66.4.532 
 
175. Kaufer DI. Pharmacologic treatment expectations in the management of dementia 
with Lewy bodies. Dem Geriatr Cog Dis 2004; 17 (1): 32-39. DOI:10.1159/000074680 
 
176. Antoniades CA, Bak TH, Carpenter RHS, Hodges JR, Barker RA. Diagnostic 
potential of saccadometry in progressive supranuclear palsy. Biomark Med 2007; 1 (4): 
487-490. DOI:10.2217/17520363.1.4.487 
 
177. Kumbier E, Kornhuber M. Delusional parasitosis in multiple system atrophy. 
Nervenarzt 2002; 73 (4): 380-383. DOI:10.1007/s00115-002-1273-8 
 
178. Pinkhardt EH, Kassubek J, Sussmuth S, Ludolph AC, Becker W, Jurgens R. 
Comparison of smooth pursuit eye movement deficits in multiple system atrophy and 
Parkinson’s disease. Journal of Neurology 2009; 256 (9): 1438-1446. 
DOI:10.1007/s00415-009-5131-5 
 
  
55 
179. Ekker MS, Janssen S, Nonnekes J, Bloem BR, de Vries NM. Neurorehabilitation for 
Parkinson’s disease: Future perspectives for behavioral adaptation. Park Rel Disord 2016; 
22 (1): S73-S77. DOI:10.1016/j.parkreldis.2015.08.031 
 
180. Rey GJ, Tomer R, Levin BE, Sanchez-Ramos J, Bowen B, Bruce JH. Psychiatric 
symptoms, atypical dementia, and left visual-field inattention in corticobasal ganglionic 
degeneration. Movement Disord 1995; 10 (1): 106-110. DOI:10.1002/mds.870100117 
 
181. Formaglio M, Krolak-Salmon P, Tilikete C, Bernard M, Croisile B, Vighetto A. 
Homonymous hemianopia and posterior cortical atrophy. Rev Neurol 2009: 165 (3): 256-
262. DOI:10.1015/j.neurol.2008.10.010 
 
182. Di Fabio RP, Zampieri C, Tuite P. Gaze control and foot kinematics during stair 
climbing: Characteristics leading to fall risk in progressive supranuclear palsy. Phys 
Therapy 2008; 88 (2), 240-250. DOI:10.2522/ptj.20070159 
 
183. Hill E, Stuart S, Lord S, Del Din S, Rochester L. Vision, visuo-cognition and 
postural control in Parkinson’s disease: An associative pilot study. Gait and Posture 2016 
Jul; 48: 74-76. DOI:10.1016/j.gaitpost.2016.04.024 
 
184. Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, Devick S, Cronin R, 
Adler CH. Abnormal visual contrast acuity in Parkinson’s disease. J Park Dis 2015; 5 (1): 
125-130. DOI:10.3233/JPD-140470 
 
185. Alvarez FJ. Parkinson’s disease, antiparkinson medicines, and driving. Expert Rev 
Neurotherapeut 2016; 16 (9): 1023-1032. DOI:10.1080/14737175.2016.1218278 
 
 
